StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.42+0.01 (+3.28%)

Close on Nov 19, 2026Market cap $117.02MP/E –Yield –

Akebia Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Akebia Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $40.26M. For fiscal 2025 it was $67.70M. The highest annual figure on record is $67.70M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$67.70M–
FY2024Dec 31, 2024-$40.69M–
FY2023Dec 31, 2023-$23.38M–
FY2022Dec 31, 2022-$73.27M–
FY2021Dec 31, 2021-$253.02M–
FY2020Dec 31, 2020-$110.71M–
FY2019Dec 31, 2019-$264.10M–
FY2018Dec 31, 2018-$99.10M–
FY2017Dec 31, 2017-$57.78M-204.6%
FY2016Dec 31, 2016$55.24M–
FY2015Dec 31, 2015-$52.82M–
FY2014Dec 31, 2014-$27.71M–
FY2013Dec 31, 2013-$11.35M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.45M-89.0%
Q1 FY2026Mar 31, 2026-$21.27M–
Q4 FY2025Dec 31, 2025$31.06M–
Q3 FY2025Sep 30, 2025$28.03M–
Q2 FY2025Jun 30, 2025$22.22M–
Q1 FY2025Mar 31, 2025-$13.61M–
Q4 FY2024Dec 31, 2024-$4.47M–
Q3 FY2024Sep 30, 2024-$6.70M–
Q2 FY2024Jun 30, 2024-$10.10M-378.2%
Q1 FY2024Mar 31, 2024-$19.43M–
Q4 FY2023Dec 31, 2023-$2.31M–
Q3 FY2023Sep 30, 2023-$7.17M-121.2%
Q2 FY2023Jun 30, 2023$3.63M–
Q1 FY2023Mar 31, 2023-$17.54M–
Q4 FY2022Dec 31, 2022-$54.68M–
Q3 FY2022Sep 30, 2022$33.81M–
Q2 FY2022Jun 30, 2022-$30.66M–
Q1 FY2022Mar 31, 2022-$21.73M–
Q4 FY2021Dec 31, 2021-$62.81M–
Q3 FY2021Sep 30, 2021-$56.27M–
Q2 FY2021Jun 30, 2021-$63.14M-269.8%
Q1 FY2021Mar 31, 2021-$70.81M–
Q4 FY2020Dec 31, 2020-$31.10M–
Q3 FY2020Sep 30, 2020-$27.19M-421.4%
Q2 FY2020Jun 30, 2020$37.18M–
Q1 FY2020Mar 31, 2020-$89.59M–
Q4 FY2019Dec 31, 2019-$92.36M–
Q3 FY2019Sep 30, 2019$8.46M–
Q2 FY2019Jun 30, 2019-$40.34M-557.3%
Q1 FY2019Mar 31, 2019-$139.86M–
Q4 FY2018Dec 31, 2018-$74.53M–
Q3 FY2018Sep 30, 2018-$12.77M–
Q2 FY2018Jun 30, 2018$8.82M-63.6%
Q1 FY2018Mar 31, 2018-$20.63M–
Q4 FY2017Dec 31, 2017-$16.83M-117.6%
Q3 FY2017Sep 30, 2017-$55.21M–
Q2 FY2017Jun 30, 2017$24.22M–
Q1 FY2017Mar 31, 2017-$9.96M–
Q4 FY2016Dec 31, 2016$95.62M–
Q3 FY2016Sep 30, 2016-$29.50M–

More Akebia Therapeutics figures

See a number that looks wrong?